What Are Senolytics? Definition and How They Work
Senolytics selectively remove senescent cells by disrupting the survival pathways those cells depend on. What the term means, what has been shown, and what has not.
The Short Answer
Senolytics are compounds that selectively induce death in senescent cells while sparing healthy ones, by disrupting the anti-apoptotic pathways that senescent cells depend on for survival. The category includes the drug combination dasatinib plus quercetin, the flavonol fisetin, navitoclax and other BCL-2 family inhibitors, and several agents in development. In mice, intermittent senolytic dosing reduces senescent cell burden, lowers inflammatory signalling, improves physical function and extends lifespan even when started late in life. In humans, early-phase trials are in progress and none has published a positive result on a clinical endpoint, which makes senolytics the most mechanistically compelling and least clinically established category in longevity practice.
What a Senescent Cell Is
Cellular senescence is a permanent exit from the cell cycle triggered by damage: critically short telomeres, DNA damage, oncogene activation or persistent stress. The cell survives but never divides again.
This is protective in the short term, because a damaged cell that cannot divide cannot become a tumour, and it is essential in wound healing and development. The problem is accumulation, and it has two components.
First, senescent cells resist apoptosis. They upregulate anti-apoptotic pathways, which is why they persist rather than being cleared, and it is exactly this dependence that senolytics exploit.
Second, they are not inert. They secrete a mixture of inflammatory cytokines, chemokines, growth factors and matrix-degrading enzymes known as the senescence-associated secretory phenotype. This drives inflammation in surrounding tissue, degrades the extracellular matrix, and can induce senescence in neighbouring cells, so a small population produces effects out of proportion to its size.
Transplanting a relatively small number of senescent cells into young mice is sufficient to produce measurable physical dysfunction, which is among the more persuasive demonstrations that these cells are causal rather than incidental.
How Senolytics Work
The mechanism is elegant and it explains the unusual dosing schedule.
Senescent cells depend on specific survival pathways to override the apoptotic signals their damaged state generates. These include BCL-2 family proteins, PI3K and AKT signalling, and p53-related pathways, and the specific dependencies differ by cell type. Disrupting a pathway a senescent cell is depending on tips it into apoptosis, while a healthy cell that is not depending on that pathway is unaffected.
This selectivity is why the approach is plausible, and it is also why the dosing is intermittent. The objective is to eliminate a cell population that accumulated over months or years, not to maintain a drug concentration. Once cleared, the population does not return immediately. Trial regimens therefore use short high-dose pulses, commonly two or three consecutive days, repeated at monthly or longer intervals. Continuous daily dosing is not the regimen that produced any of the notable results and undermines the selectivity argument, since sustained exposure gives healthy cells a longer window in which to be affected.
The Main Senolytic Agents
- Dasatinib plus quercetin. The original combination, pairing a prescription tyrosine kinase inhibitor with a flavonoid. Each clears different senescent cell types, so the combination is broader than either alone. Used in most early human trials.
- Fisetin. A flavonol found in strawberries, identified as the most effective agent in a screen of natural compounds. Available without prescription, poorly bioavailable, and dosed in human trials at roughly 20 mg per kilogram for two to three consecutive days.
- Navitoclax and other BCL-2 inhibitors. Potent and effective in animal work, with dose-limiting effects on platelets that constrain clinical use.
- Quercetin alone. Weaker than in combination, and with a real interaction profile through cytochrome P450 inhibition.
- Senomorphics. A distinct approach that suppresses the secretory phenotype without killing the cells. Different risk profile, and it requires continuous rather than intermittent dosing since the cells remain.
- Immune-based approaches. Vaccines and engineered immune cells targeting senescent cell surface markers, in preclinical development, and conceptually the most precise route.
What Has and Has Not Been Shown
Shown in animals. Reduced senescent cell burden across multiple tissues. Reduced circulating inflammatory markers. Improved physical function, cardiac function and metabolic measures. Extended median and maximum lifespan in progeroid and naturally aged mice, including when dosing began in already-old animals, which is a considerably higher bar than dosing from youth.
Shown in early human work. Tolerability in small cohorts. Changes in some senescence-associated markers in specific tissues in small studies, including work in diabetic kidney disease and idiopathic pulmonary fibrosis populations.
Not shown in humans. Any positive result on a clinical endpoint. Any effect on a biological age measure or the pace of aging. Any safety data at the multi-year cadence people adopt. Any established dosing schedule for healthy adults.
That last set of gaps is the entire practical point. The mechanism is compelling, the animal data are strong, and the human evidence does not yet exist. Those statements are all simultaneously true, and conflating the first two with the third is the characteristic error in this category.
The Open Questions That Matter
Three genuine uncertainties should temper enthusiasm, and they are scientific rather than regulatory.
Senescent cells have functions. They participate in wound healing, tissue remodelling and tumour suppression. Clearing them is not uniformly beneficial at every moment, and the animal evidence supports clearance in old animals with high burden rather than repeated clearance in healthy middle age. Nobody currently knows the answer for the second case.
Tissue and cell-type specificity. Different senescent cell types depend on different survival pathways, so no single agent clears all of them, and clearing some populations may matter more than others.
Measurement. There is no validated, accessible biomarker of senescent cell burden in humans. Without one, an individual has no way of knowing whether a senolytic protocol has done anything, which makes self-directed use unfalsifiable.
Practical Position
Senolytics belong in the experimental category, which in AEONNN's framework is Evidence Level C: educational and experimental rather than substantiated.
For anyone choosing to proceed regardless, three things follow from the evidence. The intermittent regimen from the trials is the only one with supporting rationale. The interaction checks are not optional, since fisetin and quercetin inhibit cytochrome P450 enzymes and have antiplatelet activity, which matters alongside anticoagulant therapy and before any procedure. And anyone with an active cancer history, on immunosuppressive therapy, or in the perioperative period should be having a clinical conversation rather than following a protocol from a forum.
The review trigger for this category is external rather than internal. Senolysis is not perceptible, so the sensible point to revisit is the publication of human trial results, several of which are in progress.
The AEONNN Perspective
Senolytics are the clearest case for why AEONNN separates Evidence Levels visibly rather than presenting all compounds with uniform confidence. Level C means experimental and educational, and a member should be able to see the difference between a compound with a large positive human trial and one with a striking mouse result without having to infer it.
They map to Inflammation and Immune Defense through the senescence-associated secretory phenotype and to the Longevity meta-Pillar. The Safety layer does more work than the Evidence layer here: cytochrome P450 inhibition, antiplatelet activity and cancer history are all gating considerations that resolve before efficacy is weighed.
The absence of an accessible senescence biomarker is also a specific and honest limitation. AEONNN cannot tell a member whether a senolytic protocol has worked, because no validated measure exists, and saying so is more useful than constructing a proxy that would imply knowledge nobody has. The Innovation layer tracks this area precisely because the trials in progress will change the answer.
Pillar Matrix mapping
Inflammation and Immune Defense, Longevity and Biological Age
Database Matrix layers
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Innovation Layer (bioRxiv preprints, patent filings)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
What does senolytic mean?
A compound that selectively induces death in senescent cells while sparing healthy ones, by disrupting the anti-apoptotic survival pathways senescent cells depend on. Senomorphics are a distinct category that suppress the secretory phenotype without killing the cells.
Are senolytics proven in humans?
No. Early-phase trials have examined tolerability and some tissue markers, and none has published a positive result on a clinical endpoint. The compelling evidence is from mice, including lifespan extension when dosing began in already-old animals.
Why are senolytics taken intermittently?
Because the objective is to eliminate an accumulated cell population rather than maintain a drug concentration. Trial regimens use two to three consecutive high-dose days repeated at monthly or longer intervals. Continuous dosing undermines the selectivity that makes the approach plausible.
Which senolytic is most studied?
Dasatinib plus quercetin has the most human trial history, since each clears different senescent cell types. Fisetin was the most effective single agent in a screen of natural compounds and does not require a prescription.
Can senescent cell burden be measured?
Not with any validated, accessible human biomarker. This is a significant practical limitation, because without one an individual cannot know whether a senolytic protocol has done anything.
Is clearing senescent cells always good?
Not necessarily. Senescent cells participate in wound healing, tissue remodelling and tumour suppression. The animal evidence supports clearance in old animals with high burden and says nothing about repeated clearance in healthy middle age.
Who should avoid senolytics?
Anyone with an active or recent cancer history, on immunosuppressive therapy, on anticoagulant or antiplatelet therapy, or approaching a procedure, without clinical involvement. Fisetin and quercetin inhibit cytochrome P450 enzymes and have antiplatelet activity.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.